Study: PET/MRI shows promise in restaging of prostate cancer

12/26/2012 | AuntMinnie.com (free registration)

Choline-PET/MRI identified more suspicious lesions compared with PET/CT in 31 patients with recurrent prostate cancer, according to a study presented at a radiology meeting. The study also found that PET/MRI performs comparably with PET/CT in identifying lymph node metastases and bone metastases. The findings indicate a fully diagnostic choline-PET/MRI protocol for restaging prostate cancer is well-tolerated and feasible in patients, researchers said.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park